Voglibite-GM 1/0.3 Tablet SR
Marketer
Corona Remedies Pvt Ltd
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.3mg)
Overview Voglibite-GM 1/0.3 Tablet SR
Glycemicontrol Duo 1/0.3mg Extended-Release tablets are classified as antidiabetic medications. This dual-action formulation is indicated for managing type 2 diabetes in adults, effectively regulating blood glucose. Glycemicontrol Duo 1/0.3mg Extended-Release tablets should be administered with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on your blood sugar response. Continued use is crucial, even with controlled glucose levels or feeling well; abrupt cessation can elevate blood sugar, increasing the risk of complications such as nephropathy, retinopathy, neuropathy, and peripheral vascular disease. This medication complements a comprehensive diabetes management plan, including dietary modifications, regular physical activity, and weight management as recommended by your doctor. Lifestyle adjustments are paramount in diabetes control. The most prevalent adverse effect is hypoglycemia (low blood sugar). Learn to identify hypoglycemic symptoms—sweating, dizziness, headache, tremors—and appropriate countermeasures. Maintain regular mealtimes and carry a readily available fast-acting glucose source (e.g., sugary snacks, fruit juice). Alcohol consumption increases hypoglycemia risk and should be avoided. Other potential side effects include altered taste, nausea, diarrhea, abdominal discomfort, cephalalgia, edema, visual disturbances, bone fractures, and upper respiratory infections. Weight gain may occur in some individuals. This medication is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Individuals with a history of cardiovascular disease should inform their physician before initiating treatment. Consult your doctor before use if pregnant or breastfeeding. Regular blood glucose monitoring is essential, along with potential blood tests to track blood cell counts and liver function.
Uses of Voglibite-GM 1/0.3 Tablet SR
Managing type 2 diabetes
Major Benefits of Voglibite-GM 1/0.3 Tablet SR:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Voglibite-GM 1/0.3 Tablet SR whole; do not crush, chew, or divide it. Administer this extended-release tablet on an empty stomach.
Common Side effects of Voglibite-GM 1/0.3 Tablet SR:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Voglibite-GM 1/0.3 Tablet SR:
Follow your doctor's instructions precisely regarding dosage and treatment length for Voglibite-GM 1/0.3 Tablet SR. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Administer on an empty stomach.
How Voglibite-GM 1/0.3 Tablet SR works:
Voglibite-GM 1/0.3 Extended-Release tablet comprises a triple-drug formulation for diabetes management.
SAFETY ADVICE
AlcoholUNSAFE
Combining Voglibite-GM 1/0.3 Tablet SR and alcohol is unsafe.
PregnancyCONSULT YOUR DOCTOR
The use of Voglibite-GM 1/0.3 Tablet SR during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible risks prior to prescribing. Physician consultation is recommended.
Breast feedingCONSULT YOUR DOCTOR
The extended-release Voglibite-GM 1/0.3 tablet likely poses a safety risk for breastfeeding individuals. Available human data indicate potential transfer to breast milk, with the possibility of infant harm.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyUNSAFE
Voglibite-GM 1/0.3 SR tablets pose a likely risk for individuals with kidney impairment and should be omitted. Medical advice is recommended. Moreover, this medication is unsuitable for patients experiencing severe kidney dysfunction.
LiverCAUTION
Patients with liver impairment should use Voglibite-GM 1/0.3 Tablet SR cautiously, potentially requiring dose modification. A physician's consultation is advised. In those with mild to moderate liver disease, Voglibite-GM 1/0.3 Tablet SR is typically initiated at a reduced dosage; however, it's contraindicated in patients with severe hepatic dysfunction.
What if you forget to take Voglibite-GM 1/0.3 Tablet SR :
Should you forget a Voglibite-GM 1/0.3 Tablet SR dose, take it immediately. Nevertheless, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Voglibite-GM 1/0.3 Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Therapy | Diabetes Medication |
3,018 People bought this recently